The choice of therapeutic regimen and drug doses is determined by clinical and laboratory signs of disease activity (fever, weight loss, dysproteinemia, increased ESR), the severity and rate of progression of damage to internal organs (kidneys, nervous system, gastrointestinal tract), the severity of arterial hypertension, and the presence of active HBV replication.